– USA, CA – Eiger BioPharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted therapies for Orphan Designation diseases, announced today the appointment of Thomas J. Dietz, Ph.D. to its Board of Directors as an independent director effective October 19, 2015.

Dr. Dietz has more than 20 years of successful life-sciences industry experience. Thomas Dietz is Chairman and CEO of Waypoint Holdings. Dr. Dietz was previously co-CEO and then CEO and a Director of Pacific Growth Equities from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as Head of the Investment Banking Division at Wedbush until November 2010. Prior to becoming the CEO at Pacific Growth, Dr. Dietz served as the Director of Equities Research and was an award-winning biotechnology and biopharmaceutical analyst. He was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz serves as Chairman of Galleon Pharmaceuticals, AgBiome and Virobay, and is a board member of Paratek Pharmaceuticals and Glialogix. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.

“The addition of Tom Dietz further enhances the Board’s pharmaceutical industry expertise,” stated David Cory, President and Chief Executive Officer. “Tom’s extensive experience and knowledge will enable him to provide important advice as Eiger moves through the next stage of its corporate evolution.”

“Eiger is embarking on an exciting pathway with multiple, clinical stage orphan programs, with well-characterized assets,” stated Dr. Dietz. “I look forward to working with the Eiger board and seasoned management team to capitalize upon these assets and to create shareholder value.”

About Eiger

Eiger is a privately held biotechnology company focused on the development and commercialization of innovative therapies for Orphan Designation diseases. The company is focused on developing lonafarnib for the treatment of Hepatitis Delta Virus (HDV), the most severe form of viral hepatitis. Lonafarnib is not approved for sale.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.